Michael Pisetsky Sells 3,460 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,460 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $19.62, for a total transaction of $67,885.20. Following the sale, the senior vice president owned 228,436 shares in the company, valued at $4,481,914.32. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

SiBone Trading Up 4.9%

Shares of NASDAQ:SIBN opened at $21.40 on Thursday. The company has a 50 day moving average of $18.71 and a 200-day moving average of $17.07. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The firm has a market cap of $928.55 million, a P/E ratio of -41.96 and a beta of 0.69. SiBone has a twelve month low of $12.49 and a twelve month high of $21.49.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. As a group, analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares during the period. Tudor Investment Corp ET AL lifted its position in shares of SiBone by 0.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock valued at $3,798,000 after acquiring an additional 1,968 shares in the last quarter. Rhumbline Advisers boosted its stake in SiBone by 3.6% in the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after purchasing an additional 2,100 shares during the period. Franklin Resources Inc. boosted its stake in SiBone by 8.3% in the 3rd quarter. Franklin Resources Inc. now owns 29,018 shares of the company’s stock worth $427,000 after purchasing an additional 2,228 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in SiBone during the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

SIBN has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Needham & Company LLC upped their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Truist Financial raised their price objective on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Morgan Stanley boosted their target price on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Canaccord Genuity Group increased their target price on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.